Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma

Archives of Ophthalmology

Volumn 114, Issue 11, 1996, Pages 1396-1401

  Shternfeld, Ilona Slusker ^a   Lasudry, Jacques G H ^a   Chappell, Richard J ^a   Darjatmoko, Soesiawati R ^a   Albert, Daniel M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA;

EID: 0029966737     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100140596012     Document Type: Article

References (53)

1. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors: are they radiation-induced? Ophthalmology. 1984; 91:1351-1355.
2. Verhoeff FH, Jackson E. Minutes of the proceedings: 62nd annual meeting. Trans Am Ophthalmol Soc. 1926;24:38-43.
3. Verhoeff FH. Glioma retinae treated by x-rays with apparent destruction of the tumor and preservation of vision. Arch Ophthalmol. 1921;50:450-456.
4. Gallie BL, Squire JA, Goddard A, et al. Mechanism of oncogenesis in retinoblastoma. Lab Invest. 1990;62:394-408.
5. Verhoeff FH. Retinoblastoma undergoing spontaneous regression-calcifying agent suggested in treatment of retinoblastoma. Am J Ophthalmol. 1966;62:573-574.
6. Albert DM, Saulenas AM, Cohen SM. Verhoeff's query: is vitamin D effective against retinoblastoma? Arch Ophthalmol. 1988;106:536-540.
7. Saulenas AM, Cohen SM, Key LL, Winter C, Albert DM. Vitamin D and retinoblastoma: the presence of receptors and inhibition of growth in vitro. Arch Ophthalmol. 1988;106:533-535.
8. Albert DM, Marcus DM, Gallo JP, O'Brien JM. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci. 1992;33:2354-2364.
9. Cohen SM, Saulenas AM, Sullivan CR, Albert DM. Further studies of the effect of vitamin D on retinoblastoma-inhibition with 1,25-dihydroxycholecalciferol. Arch Ophthalmol. 1988;106:541-543.
10. Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new treatment potential. Endocr Rev. 1992;13:765-784.
11. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP. Novel vitamin D analogs that modulate leukemic cell growth: a differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood. 1989;74:82-93.
12. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood. 1991;78:75-82.
13. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 1990;50:6857-6864.
14. 3 metabolites. Cancer Res. 1983;43:4443-4447.
15. Brown AJ, Dusso A, Slatopolsky E. Selective vitamin D analogs and their therapeutic applications. Semin Nephrol. 1994;14:156-174.
16. Windle JJ, Albert DM, O'Brien JM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
17. Kivela T, Virtanen I, Marcus DM, et al. Neuronal and glial properties of a transgenic retinoblastoma model. Am J Pathol. 1991;138:1135-1148.
18. O'Brien JM, Marcus DM, Niffenegger AS, et al. Trilateral retinoblastoma in transgenic mice. Trans Am Ophthalmol Soc. 1989;87:301-326.
19. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med. 1989;320:980-991.
20. Pols HAP, Birkenhager JC, van Leeuwen JPTM. Vitamin D analogues: from molecule to clinical application. Clin Endocrinol. 1994;40:285-291.
21. Brenner RV, Shabahang M, Schumaker LM, et al. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells. Cancer Lett. 1995; 92:77-82.
22. Schwarte GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res. 1994; 14:1077-1082.
23. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990;87:3929-3932.
24. 3. Molec Endocrinol. 1995;9:1814-1824
25. Dusso AS, Negrea L, Gunawardhana S, et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology. 1991;128:1687-1692.
26. 3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2). J Bone Miner Res. 1991:6:893-899.
27. 3 analogues. Eur J Pharmacol. 1990;178:247-250.
28. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia. 1994;8:1453-1457.
29. Schweigerer L. Antiangiogenesis: a novel therapeutic concept in pediatric oncology. J Mol Med. 1995;73:497-508.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182-1186.
31. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972;175:409-416.
32. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1995;36:83-87.
33. Albert DM, Tapper D, Robinson NL, Felman R. Retinoblastoma and angiogenesis activity. Retina. 1984;4:189-194.
34. Schweigerer L, Neufeld G, Gospodarowicz D. Basic fibroblast growth factor is present in cultured human retinoblastoma cells. Invest Ophthalmol Vis Sci. 1987;28:1838-1843.
35. Shields, JA, Augsburger JJ. Current approaches to the diagnosis and management of retinoblastoma. Surv Ophthalmol. 1981;25;347-372.
36. Weidner N, Carroll PR, Flax J,Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
37. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast cancer. J Natl Cancer Inst. 1992;84:1875-1887.
38. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol. 1995;177:57-63.
39. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer. 1993;55:739-744.
40. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of angiogenesis. Cancer Metastasis Rev. 1995;14:263-277.
41. Bouillon R, Verstuyf A, Verlinden L, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol. 1995;50:577-583.
42. Reitsma PH, Rothberg PG, Astrin SM, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature. 1983;306:492-494.
43. 3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28:110-114.
44. White L. Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol. 1991;13:189-201.
45. Ferris FL III, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114:1412.
46. 3, and analogs. J Cell Biochem. 1994; 56:427-435.
47. 3 and their combination. Cancer Lett. 1993;75:35-39.
48. Brem H, Gresser I, Grosfeld J, Folkman J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg. 1993; 28:1253-1257.
49. Teicher BA, Sotomayer EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992;52:6702-6704.
50. Helton KJ, Fletcher BD, Kun LE, Jenkins, Pratt CB. Bone tumors other than osteosarcoma after retinoblastoma. Cancer. 1993;71:2847-53.
51. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671.
52. Abramson DH, Ellsworth RM, Zimmerman LE. Nonocular cancer in retinoblastoma survivors. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:454-457.
53. Tucker MA, D'Angio GJ, Boice JD, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588-593.